Diabetes prevention program for older adults
BRInging the Diabetes Prevention Program to GEriatric Populations
This study is testing whether a diabetes prevention program delivered online or in person can help older adults with prediabetes lose weight and stay engaged over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 230 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05166785 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a Diabetes Prevention Program (DPP) tailored for older adults, comparing a telehealth version to an in-person version. It will recruit participants aged 65 and older with prediabetes and assess outcomes such as weight loss and program attendance over a 12-month period. The study will utilize a randomized controlled trial design with 230 participants, focusing on delivering an evidence-based intervention to a growing population at risk of diabetes. The findings will help inform best practices for implementing diabetes prevention strategies in community and rural settings.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 65 and older with a diagnosis of prediabetes and a BMI of 30 or greater.
Not a fit: Patients with prevalent diabetes, severe cognitive issues, or those unable to participate due to health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce the risk of diabetes in older adults, improving their overall health and quality of life.
How similar studies have performed: Previous studies have shown success with similar diabetes prevention programs, particularly among older adults, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged 65 years and older * Diagnosis of pre-diabetes (A1c between 5.7-6.4%, fasting glucose between 100-125 mg/dL, or oral glucose tolerance test between 140-199 mg/dL within past 12 months) * BMI of greater than or equal to 30 * English-speaking * Under the care of a Primary care provider (PCP) in the NYU Langone Health system * Able to travel to NYU Langone for in-person evaluations * Access to a telephone * Informed consent Exclusion Criteria: * Prevalent diabetes or end-stage renal disease * Prior participation in the Diabetes Prevention Program * A documented current history of active psychosis or other cognitive issues via International Classification of Diseases (ICD) -10 codes * Taking FDA-approved weight loss medications * PCP stating that patient should not participate * Inability to communicate due to severe, uncorrectable hearing loss or speech disorder * Severe visual impairment that precludes completion of assessments and/or intervention
Where this trial is running
New York, New York
- NYU Langone Health — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Jeannette M Beasley, PhD, RDN — NYU Langone Health
- Study coordinator: Shneha Pradhan
- Email: Bridgestudy@nyulangone.org
- Phone: 646-501-4681
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.